Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies targeting neurological and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, long COVID, and advanced liver cirrhosis. Its key products include bezisterim, an oral anti-inflammatory agent addressing neuroinflammation and insulin resistance, and BIV201, a novel terlipressin formulation for liver disease complications. BioVie focuses on advancing clinical trials and leveraging proprietary formulations and intellectual property to address significant unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.